Michael Andersson
University of Copenhagen · 151 works · 16,745 citations · h-index 46
Top works
- Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
- Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial
- Trastuzumab Beyond Progression in Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: A German Breast Group 26/Breast International Group 03-05 Study
- Risk of Second Malignant Neoplasms Among Long-term Survivors of Testicular Cancer
- Second Cancers Among 40 576 Testicular Cancer Patients: Focus on Long-term Survivors
- Breast Cancer Following Radiotherapy and Chemotherapy Among Young Women With Hodgkin Disease
- Second Malignant Neoplasms Among Long-Term Survivors of Hodgkin’s Disease: A Population-Based Evaluation Over 25 Years
- 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial
- Risk of Leukemia after Platinum-Based Chemotherapy for Ovarian Cancer
- Second Cancers Among Long-Term Survivors of Hodgkin’s Disease Diagnosed in Childhood and Adolescence
- Phase III Randomized Study Comparing Docetaxel Plus Trastuzumab With Vinorelbine Plus Trastuzumab As First-Line Therapy of Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: The HERNATA Study
- Long-Term Solid Cancer Risk Among 5-Year Survivors of Hodgkin's Lymphoma
- Second Cancers Among 104760 Survivors of Cervical Cancer: Evaluation of Long-Term Risk
- Adjuvant Chemotherapy With Sequential or Concurrent Anthracycline and Docetaxel: Breast International Group 02 98 Randomized Trial
- Lung Cancer after Treatment for Hodgkin's Disease: Focus on Radiation Effects
- Noncancer Causes of Death in Survivors of Testicular Cancer
- Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up
- Suicide After Breast Cancer: an International Population-Based Study of 723 810 Women
- The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial
- Adjuvant anthracycline in breast cancer. Improved outcome in premenopausal patients following substitution of methotrexate in the CMF Combination with epirubicin